Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 3/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 5/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669956 | 0.89 | COMT (0.55) | COMTFTOSLC22A12XDHGCGR | |
| SCHEMBL32669777 | 0.87 | SLC22A12 (0.43) | COMTFTOSLC22A12XDHGCGR | |
| SCHEMBL32669684 | 0.81 | FTO (0.47) | COMTFTOALDH1A1HPGDPOLB | |
| SCHEMBL32669869 | 0.81 | RAB9A (0.42) | SLC22A12 | |
| SCHEMBL32670129 | 0.81 | MEN1 (0.40) | COMTFTOSLC22A12XDHGCGR | |
| SCHEMBL32669769 | 0.79 | SLC22A12 (0.35) | COMTFTOSLC22A12XDHGCGR | |
| SCHEMBL30740985 | 0.75 | FTO (0.48) | FTOSLC22A12XDHGCGRF11 | |
| SCHEMBL32669494 | 0.73 | FTO (0.67) | COMTFTOGCGRALDH1A1HPGD | |
| SCHEMBL32669736 | 0.71 | FTO (0.81) | COMTFTO | |
| SCHEMBL32669656 | 0.71 | FTO (0.49) | COMTFTOSLC22A12ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | COMT 52/4885FTO 1/4885SLC22A12 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.